The results of this meta-analysis showed that the experimental group treated with SGLT-2 inhibitors demonstrated significantly better outcomes than the control group in terms of LVEDVI, BNP, KCCQ, and NT-proBNP, indicating that SGLT-2 inhibitors can be an effective treatment for patients with HF complicated by T2DM. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.